PFEGuruFocus·May 31, 2026 at 09:00 AM

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B

Source: GuruFocus

More PFE News

Is Pfizer Stock a "Value Trap" or a Generational Opportunity?

The Motley Fool·4h ago

How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers

Investors Business Daily·8h ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Business Wire·8h ago

Mailbag: A Follow-Up on Pfizer & Other Questions

ETF Trends·1 day ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

GuruFocus·1 day ago